Pharmacological properties
The pharmacologically active components of the drug are Guaifenesin and an extract from medicinal plants, which has a predominantly sedative effect. The sedative effect of the extract is combined with the muscle relaxant effect of guaifenesin (relaxes smooth muscles).
Guaifenesin is rapidly absorbed from the gastrointestinal tract, metabolized in the liver by conjugation with glucuronic acid, and excreted as inactive metabolites, mainly in the urine.
Indication
Mild form of neurasthenia, especially if accompanied by anxiety, fear, sadness, restlessness, irritability, dullness of attention or fatigue, sleep disturbance, insomnia, exhaustion or neurotic memory disorders. supportive therapy for migraine, headache caused by nervous tension, vascular psychosomatic disorders with neurocirculatory asthenia, neuromuscular excitability, pain in the face, with climacteric syndrome. functional diseases of the gastrointestinal tract (dyspeptic syndrome, irritable bowel syndrome). psychosomatic dermatosis accompanied by itching (urticaria, atopic eczema).
Application
Usually prescribed 5 ml (1 teaspoon) of the drug 3 times a day. If necessary, the dose can be increased to 10 ml 3 times a day or reduced to 2.5 ml in the morning and afternoon and 5 ml in the evening. The dose can be changed according to the patient's condition.
The interval between individual doses should be from 4 to 6 hours. The maximum daily dose is 30 ml.
The drug can be mixed with drinks (juice, tea).
Contraindication
Hypersensitivity to the active components or excipients of the drug, myasthenia gravis, epilepsy.
Side effects
Quiet is well tolerated by patients, however, the following side effects are possible:
from the nervous system: rarely - dizziness, drowsiness;
from the digestive tract: rarely - nausea, vomiting, cramps, heartburn, diarrhea or constipation;
Skin: rarely - rash, itching;
Musculoskeletal system: rarely - mild muscle weakness;
general disorders: rarely - fatigue.
Special instructions
While using the drug, patients, especially those with fair skin, should avoid prolonged exposure to ultraviolet radiation (sunbathing, solarium, diathermy).
The drug should be used with caution in severe liver diseases, intoxication with substances that suppress the action of the CNS.
The drug contains 11.72 vol.% ethanol, one dose (2.5 ml) contains 0.231 g of ethanol, which must be taken into account when used during pregnancy, breastfeeding, children and risk groups (patients with liver diseases, epilepsy, alcoholism).
The drug is contraindicated in people with rare hereditary problems of fructose intolerance or glucose-galactose malabsorption.
Use during pregnancy and breastfeeding
Pregnancy. No reproductive studies have been conducted during the use of the drug; the safety of the drug during pregnancy has not been established. In this regard, the drug Quiet can be prescribed during pregnancy only in exceptional cases. Before its use, especially in the first trimester, it is necessary to assess the ratio of the potential risk to the fetus and the expected benefit to the pregnant woman.
Breastfeeding. It is not known whether Guaifenesin and other active components of the drug are excreted in breast milk, therefore, the potential risk of exposure to the drug for the child should be carefully compared with the possible benefit to the mother.
Ability to influence the reaction rate when driving vehicles or working with other mechanisms. Due to the fact that Quiet contains ethanol and Guaifenesin, its use may lead to inhibition of the reaction, which manifests itself individually in each patient. Therefore, it is worth refraining from potentially dangerous activities that require increased attention, such as driving vehicles or working with other mechanisms.
Children. The drug is used in children aged 12 years and older.
Interactions
Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acid and enhances the effects of alcohol and other CNS depressants. Centrally acting muscle relaxants may enhance the undesirable effects of guaifenesin, especially muscle weakness.
Significant clinical interactions with St. John's wort have also been observed with the simultaneous use of cyclosporine, digoxin and warfarin. The interaction can lead to a decrease in the concentration of drugs in the blood plasma and, accordingly, to a decrease in the severity of the therapeutic effect. Therefore, St. John's wort should not be used with cyclosporine. If the patient is using cyclosporine, it is necessary to cancel the intake of St. John's wort and, taking into account the level of cyclosporine in the blood plasma, adjust the dosage of cyclosporine.
Concomitant use of St. John's wort with digoxin or warfarin is not recommended. If St. John's wort is necessary, monitoring of digoxin plasma levels or prothrombin time during treatment with warfarin should be performed, and the dose should be adjusted accordingly. When the dose of warfarin or digoxin is increased, the dose of St. John's wort should not be changed.
St. John's wort perforated can significantly reduce the effect of theophylline, so simultaneous use is not recommended. If it is necessary to take St. John's wort, it is necessary to monitor the level of theophylline in the blood plasma and, if necessary, adjust the dose of theophylline without changing the dose of St. John's wort.
Concomitant use with oral contraceptives may cause menstrual irregularities, bleeding, and reduced efficacy of the drug. Therefore, concomitant use of St. John's wort and oral contraceptives is not recommended.
Concomitant therapy with amitriptyline is not recommended.
Impact on laboratory test results.
Guaifenesin may cause false-positive results in diagnostic tests for 5-hydroxyindoleacetic acid (photometric method using nitrosonaphthol as a reagent) and vanillylmandelic acid in urine. Therefore, treatment with Quiet should be discontinued 48 hours before urine collection for this analysis.
Overdose
Initially manifested by CNS depression, drowsiness. Later, these symptoms may be accompanied by nausea, mild muscle weakness, joint pain, and a feeling of heaviness in the stomach.
Treatment is exclusively symptomatic and follows the general principles of treatment for overdose. There is no specific antidote.
Storage conditions
At a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.
